Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Hypercalcaemia, metastatic calcification, evidence of vitamin D toxicity, hypervitaminosis D, abnormal sensitivity to toxic effects of vitamin D; malabsorption syndrome (unless dosed appropriately).
|
|
Special Precautions
Patient with heart disease or arteriosclerosis, renal calculi, hyperphosphataemia. Obese patients (BMI >30 kg/m2). Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor serum or urinary Ca and phosphorus concentrations, and BUN initially once or twice weekly then at regular intervals; renal function as clinically indicated. Perform bone X-ray every month until the condition is stabilised and corrected. Monitor for signs and symptoms of vitamin D toxicity.
|
|
Adverse Reactions
Significant: Hypercalcaemia, soft tissue calcification, hypercalciuria, vitamin D toxicity.
Gastrointestinal disorders: Nausea, abdominal pain, vomiting, constipation.
General disorders and administration site conditions: Weakness.
Investigations: Increased serum creatinine, weight loss.
Metabolism and nutrition disorders: Anorexia, thirst.
Nervous system disorders: Headache.
Renal and urinary disorders: Polyuria, nocturia.
|
|
Drug Interactions
Mineral oil and colestyramine may interfere with the absorption of vitamin D. May cause hypercalcaemia with thiazide diuretics in hypoparathyroid patients. May reduce the efficacy with rifampicin and isoniazid. Metabolism may be increased by phenytoin. May increase the arrhythmogenic effects of cardiac glycosides.
|
|
CIMS Class
|
|
ATC Classification
A11CC01 - ergocalciferol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
|
